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Abstract
Background: Various diseases derive from pathologically altered β-cells. Their function can be increased, leading to
hyperinsulinism, or decreased, resulting in diabetes. Non-invasive imaging of the β-cell-specific glucagon-like peptide
receptor-1 (GLP-1R) would allow the assessment of both β-cell mass and derived tumours, potentially improving the
diagnosis of various conditions. We tested three new 67/68Ga-labelled derivatives of exendin-4, an agonist of GLP-1R,
in vitro and in vivo. We determined the influence of the chelator NODAGA conjugated to resident lysines either at
positions 12 and 27 or the C-terminally attached lysine at position 40 on the binding and kinetics of the peptide.
Methods: Binding and internalisation of 67Ga-labelled Ex4NOD12, Ex4NOD27 and Ex4NOD40 were tested on Chinese
hamster lung (CHL) cells stably transfected to express the GLP-1 receptor (GLP-1R). In vivo biodistribution of 68Ga-labelled
peptides was investigated in CD1 nu/nu mice with subcutaneous CHL-GLP-1R positive tumours; the specificity of the
binding to GLP-1R was determined by pre-injecting excess peptide.
Results: All peptides showed good in vitro binding affinities to GLP-1R in the range of 29 to 54 nM. 67/68Ga-Ex4NOD40
and 67/68Ga-Ex4NOD12 show excellent internalisation (>30%) and high specific uptake in GLP-1R positive tissue, but high
activity was also found in the kidneys.
Conclusions: We show that of the three peptides, Ga-Ex4NOD40 and Ga-Ex4NOD12 demonstrate the most favourable
in vitro properties and in vivo binding to GLP-1R positive tissue. Therefore, we conclude that the lysines at positions 12
and 40 might preferentially be utilised for modifying exendin-4.
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Background
β-cells are located in the islets of Langerhans and are re-
sponsible for the biosynthesis and secretion of insulin
and the regulation of blood glucose levels. A patho-
logical dysfunction of the β-cells may lead to imbalanced
blood glucose and can be the cause for several serious
diseases. Inusulinomas are β-cell-derived tumours that
secrete insulin and can cause hyperinsulinism, poten-
tially leading to both hypoglycemia and neuroglycopenic
symptoms [1]. Hyperinsulinism can also be caused by
hyperplastic β-cells that excrete excessive amounts of in-
sulin, such as those found in cases of nesidioblastosis
and congenital hyperinsulinism. An exact localisation of
the foci for both insulinoma and β-cell hyperplasia is ne-
cessary as surgical resection of the affected tissue is the
best treatment option [2-5]. All of the currently available
non-invasive imaging modalities, however, suffer from a
low sensitivity, which is especially an issue for detecting
small insulinoma [6,7].
Another serious medical condition that arises from dys-
functional β-cells is diabetes. Type 1 diabetes is caused by
an autoimmune reaction towards the β-cells leading to cell
death while type 2 diabetes results from long-term elevated
blood glucose levels induced by either apoptotic β-cells or
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due to insufficient insulin response caused by insulin recep-
tor dysfunction [8]. So far, the diagnosis of diabetes is only
possible via indirect means, e.g. determination of plasma
glucose or HbA1c, which is far from optimal since these
markers only show up after more than 80% of the islets are
lost and the progression of the disease is irreversible [9]. A
non-invasive means of determining β-cell mass might allow
an earlier discovery of a decrease, which potentially could
allow a timely intervention. Additionally, it would allow ac-
curate assessment of transplanted β-cells as a potential
treatment for diabetes, which is not possible so far.
Generally speaking, it can be stated that β-cell imaging
has the potential for an improved diagnosis and disease
management for a variety of medical conditions.
One potential target is the glucagon-like peptide
receptor-1 (GLP-1R), which is highly expressed on β-cells.
Exendin-4, an analogue of the metabolically unstable en-
dogenous ligand glucagon-like peptide-1 (GLP-1), has been
successfully used to image insulinoma in human patients
[10]. A common modification site to introduce various
moieties for different purposes to exendin-4 is the free
amine of a C-terminally attached lysine or cysteine [11-14].
Exendin-4, though, possesses two naturally occurring ly-
sines at positions 12 and 27, which might be used as modi-
fication sites as well. However, reports on how altering the
respective position affects the properties of the peptide are
conflicting. Several papers cite the importance of K12 and
K27 for the binding to the receptor while other groups
modified these positions without negative effects on the
binding affinity [15-17]. A further risk of modifying the na-
tive lysine residues is a potential steric interference with the
side chains of the neighbouring amino acids, which can
lead to a distorted secondary structure. This poses an add-
itional issue as the α-helical structure is an important factor
for the positioning of the functional groups of the amino
acids that are responsible for the binding to the receptor
[18]. Our objective in this work is to explore potential
modification possibilities of exendin-4 besides the well-
established C-terminal alterations. This might open new
possibilities combining new functional moieties and in-
crease the variety of tracers.
As native insulinoma cell lines tend to produce insulin,
which after inoculation in mice often leads to fatal
hypoglycemia, we decided to use CHL cells that were
transfected to overexpress the GLP-1 receptor in both
in vitro and in vivo experiments.
Since the number of β-cells is low (only 1% to 2% of
the pancreas mass are β-cells) and β-cell-derived tu-
mours are quite small, a sensitive detection method is
necessary [5,19]. Positron emission tomography (PET) is
ideal for this purpose as it offers a very high sensitivity
and good spatial resolution. While 64Cu is a widely used
PET nuclide, it emits β− that can lead to an increased ra-
diation burden for the patient [20]. 68Ga, a generator-
based PET nuclide used in this work, does not have this
drawback. It is widely available and useful for clinical
use. In addition, it can be both quickly and efficiently
incorporated into the chelator 1-(1,3-carboxypropyl)-
1,4,7-triazacyclononane-4,7-diacetic acid (NODAGA), a
chelator that can be used for labelling not only with
67/68Ga but also with of other radiometals like 111In and
Al18F that are suitable for imaging. [21]. Using 67Ga as a
γ-emitter might be adequate for single-photon emission
computed tomography (SPECT) imaging; however, since
it is currently not available in sufficiently high purity, it
cannot be used to label our peptides with high-enough
specific activity for in vivo experiments. Nevertheless, in
this study, it was used as a substitute for 68Ga in in vitro
experiments since it has a more convenient half-life of
3.3 days.
In this work, we investigate the influence of the site at
which the chelator NODAGA is attached to exendin-4
on its binding affinity towards the GLP-1 receptor. Spe-
cifically, we have generated three 67Ga-labelled peptides
(Ex4NOD12, Ex4NOD27 and Ex4NOD40) and mea-
sured their affinities towards GLP-1R expressed on the
surface of Chinese hamster lung (CHL) cells. We have
also assessed both their internalisation kinetics and their
stability in human blood plasma. Additionally, we
monitored the biodistribution of 68Ga-labelled peptides
in CHL-GLP-1R-positive tumour-bearing CD1 nu/nu
mice.
Methods
Radiolabelling of the exendin-4 derivatives
Ex4NOD12, Ex4NOD27 and Ex4NOD40, shown in
Figure 1, were synthetised by Peptide Specialty Laboratories
(Heidelberg, Germany). [Lys40(Ahx-DTPA)NH2]-exendin-4
(HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPP
SK(DTPA-Ahx)-NH2) and [Lys
40(DTPA)]exendin-3 (HSD
GTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK(D
TPA)-NH2), synthetised by Peptide Specialty Laboratories
were used as already established standards. The chela-
tors NODAGA and diethylene triamine pentaacetic acid
(DTPA) were conjugated to the ε-amino group of the lysine
either at position 12 or 27 with aminocaproic acid (Ahx) as
spacer or attached to a lysine, which was linked to the C-
terminal end of the peptide leading to a lysine in position
40. In either case, the C-terminal carboxyl group was ami-
dated. In order to improve oxidative stability, the methio-
nine in position 14 of Ex4NOD40 was replaced with
norleucine in both Ex4NOD12 and Ex4NOD27.
68GaCl3 was eluted from a TiO2-based 1.85 GBq
68Ge/
68Ga generator (Eckert & Ziegler, Berlin, Germany) with
0.1 N Ultrapure HCl (Merck Millipore, Switzerland).
The generator was eluted drop by drop, fractions of
200 μL each were collected, and the fractions with the
highest activity were used for labelling.
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Labelling of all peptides was performed in 4-(2-hydro-
xyethyl)-1-piperazineethanesulphonic acid (HEPES) buffer
in a final concentration of 0.25 M and pH 4.5. 0.23 to
0.41 nmol peptide was added to 60 to 77 MBq 68GaCl3,
followed by a 15-min incubation of the reaction mixture
at 90°C. For quality control, the sample was diluted in
0.1 mM sodium DTPA and analysed using reversed-phase
high-performance liquid chromatography (RP-HPLC) on
a C18 reversed-phase column (Dr. Maisch Reprospher
300 C18-TN, 46 mm× 150 mm; 5 μm). The column was
eluted with water containing 0.1% trifluoroacetic acid
(TFA), with a linear gradient from 15% to 95% acetonitrile
for 10 min followed by an isocratic elution at 95% aceto-
nitrile for additional 5 min with a flow rate of 1 mL/min.
67Ga labellings were performed using 55 to 65 MBq
67GaCl3 (Mallinckrodt, Netherlands) and 1 to 6.75 nmol
Ex4NOD40, Ex4NOD12 and Ex4NOD27 in 10 μL 0.4 M
ammonium acetate pH 5.5 and 20 μL Milli-Q water
followed by 30 min incubation at 90°C. Quality control
was performed as described above.
Cell culture
Chinese hamster lung cell line stably transfected with
the GLP-1 receptor gene (CHL-GLP-1R positive cells)
were cultured in Dulbecco's modified Eagle's medium
(DMEM) with 4.5 g/L D-glucose and GlutaMax. In
addition, the media contained 10% fetal calf serum,
100 IU/mL penicillin G, 10 mg/mL streptomycine,
500 μg/mL geneticin sulfate, 1 mM sodium pyruvate and
0.1 mM non-essential amino acids. The cells were main-
tained in a humidified 5% CO2 atmosphere at 37°C and
were harvested by trypsinisation with trypsin/EDTA.
Labelling of exendin-4 derivatives with stable isotopes
All peptides were labelled by adding 40 μL of the re-
spective 0.25 mM peptide solution and 2 μL of a 10 mM
Figure 1 Graphical representation of the three peptides. Ex4NOD12 with the chelator attached to the lysine at position 12 (red), Ex4NOD27
with the chelator attached to the lysine at position 27 (yellow) and Ex4NOD40 with a C-terminally attached lysine at position 40 (blue). The other
corresponding residues are listed in the table below.
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natGaCl3 (Sigma-Aldrich, Switzerland) solution in 60 μL
0.4 M ammonium acetate buffer (pH 5.5) followed by a
15-min incubation at 90°C. The labelling was verified by
liquid chromatography-mass spectrometry (LC/MS) on
an Atlantis C18 (25 cm × 4.6 mm; 5 μm) column.
IC50 determination
The half-maximal inhibitory concentrations (IC50) of
natGa-labelled Ex4NOD12, Ex4NOD27 and Ex4NOD40
were determined using CHL-GLP-1R positive cells
grown on six well plates (approximately 0.8 × 106 cells/
well grown overnight). The two already published pep-
tides natIn-labelled [Lys40(DTPA)]exendin-3 and [Lys40
(Ahx-DTPA)NH2]-exendin-4 were used to determine if
the cell line has an influence on the results. A 4-kBq
(120 fmol)-67Ga-labelled Ex4NOD40 was used for detec-
tion of the binding. The cells were washed twice with
PBS and incubated for 60 min on ice with 100 μL
(4 kBq; 120 fmol) 67Ga-labelled Ex4NOD40 in the pres-
ence of increasing concentrations of non-radioactive-
labelled exendin-4 derivative (10−11 to 10−6 M). The total
volume was adjusted with media (DMEM with 0.1%
BSA) to 1 mL. For the total binding, no natGa-labelled
peptide was added. After incubation with the labelled
peptides, the cells were washed twice with phosphate
buffered saline (PBS), solubilised with 1 mL sodium hy-
droxide (NaOH) and collected and the activity was
quantified using a γ-counter (Packard Cobra II Auto
Gamma, PerkinElmer, Switzerland). The IC50 values
were calculated by fitting the data with non-linear re-
gression using least squares fit with GraphPad Prism
(GraphPad Software, La Jolla, CA, USA). Experiments
were performed on triplicate samples.
Internalisation assay
The internalisation kinetics of 67Ga-Ex4NOD12, 67Ga-
Ex4NOD27 and 67Ga-Ex4NOD40 were determined using
CHL-GLP-1 receptor positive cells as described above. A
4 kBq (120 fmol) of the respective 67Ga-labelled peptide
was used as a probe. Cells were incubated for specific time
points (5, 15, 30, 60 and 120 min, respectively) at 37°C;
non-specific binding was determined by adding an add-
itional 100 μL of natGa-labelled tracer to a final concentra-
tion of 1 μM of the corresponding peptide. After
incubation, the supernatant was aspirated and the wells
were washed with 1 mL PBS. Both the supernatant and
wash fractions were pooled and used to determine the non-
bound fraction. In order to dislodge the surface-bound pep-
tide, the cells were incubated at room temperature with
1 mL glycine buffer pH 2.6 for 5 min. The glycine wash
was collected separately. The internalised fraction was iden-
tified by adding 1 mL 1 M NaOH to the cells with subse-
quent collection of the lysates. The activity in all three
fractions was measured in a γ-counter (Packard Cobra II
Auto Gamma, Perkin Elmer, Switzerland). Experiments
were performed on triplicate samples.
Plasma stability
A 5-MBq (0.2 nmol)-labelled peptide was added into
250 μL fresh human blood plasma and incubated at 37°C
for 48 h. Forty-microlitre samples were taken at specific
time points (0, 1, 4, 24, and 48 h) and mixed with 200 μL
precipitation solution (methanol/water, 0.1% TFA 1:1). The
sample was then filtered through a Thomson Single StEP
Filter vial 0.45 μm PVDF (Thomson Instrument Company,
Oceanside, CA, USA) and analysed via RP-HPLC on a Dis-
covery BioWide Pore C18 (15 cm× 2.1 mm; 3 μm) column.
The column was eluted with water containing 0.1% TFA,
with a linear gradient from 15% to 95% acetonitrile for
10 min followed by an isocratic elution at 95% acetonitrile
for an additional 5 min with a flow rate of 1 mL/min.
Biodistribution
All in vivo experiments were approved by the local veterin-
arian department and conducted in accordance with the
Swiss law of animal protection. Biodistribution studies of
68Ga-Ex4NOD12, 68Ga-Ex4NOD27 and 68Ga-Ex4NOD40
were compared. Six-week-old female CD1 nu/nu mice were
subcutaneously inoculated in both shoulder regions with
8 × 106 CHL-GLP-1R positive cells suspended in PBS
pH 7.4. After 4 weeks, the mice were randomly divided into
groups of four mice each. The mice were injected with ap-
proximately 750 kBq (3 to 8 pmol) of the respective 68Ga-
labelled peptide via the tail vein. The mice were sacrificed
at specific time points (0.5, 1, 2 h). In order to determine
GLP-1 receptor-mediated uptake, one group per peptide
was co-injected with excess (100 μg each) unlabelled pep-
tide and euthanised 2 h after injection. Blood, heart, lungs,
spleen, kidneys, pancreas, stomach, intestine, liver, muscle,
bone and tumour were removed and weighed and activity
was determined in a γ-counter (Packard Cobra II Auto
Gamma, Perkin Elmer, Switzerland). The percentage
injected activity per gram tissue (%iA/g) was calculated for
each tissue. The statistical significance was determined
using Student's unpaired t test.
Circular dichroism
Three sets of spectra were recorded for each peptide
with a concentration of 20 μM in Milli-Q water using a
Chirascan spectropolarimeter (Applied Photophysics,
UK) with a 0.1-cm path length in the range of 190 to
280 nm. First, a baseline CD spectrum was recorded at
20°C followed by thermal denaturation at 94°C for
30 min. After the denaturation, a spectrum was recorded
to determine the linearisation of the peptide. Subse-
quently, the sample was cooled to 20°C and another set
of spectra was recorded to evaluate the refolding of the
peptide.
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Results
Radiolabelling
All peptides were labelled with 67Ga with a specific activity
between 5.6 to 35 MBq/nmol. The specific activity achieved
for 68Ga labelling ranged from 71 to 163 MBq/nmol at the
time of injection. Radiochemical purity was >95% as de-
termined by HPLC. 67/68Ga-DTPA eluted from the col-
umn after 2 min whereas 67/68Ga-labelled Ex4NOD12,
Ex4NOD27 and Ex4NOD40 had a retention time of ap-
proximately 8 min.
Circular dichroism
CD spectroscopy showed partial unfolding of all peptides
after 30 min at 95°C. After subsequent cooling to 20°C,
spectra were identical to the ones taken before thermal
denaturation. This indicates a complete refolding of the
peptides into their natural α-helical structure.
IC50 binding assay
The results of the IC50 determination are shown in
Figure 2A. The IC50 for
natGa-Ex4NOD12, natGa-
Ex4NOD27 and natGa-Ex4NOD40 for binding to CHL-
GLP-1R positive cells were 29 nM (95% confidence interval
22 to 40 nM), 53 nM (95% confidence interval 38 to 73
nM) and 54 nM (95% confidence interval 39 to 76 nM), re-
spectively. The IC50 of non-modified exendin-4 was 4.1 nM
(95% confidence interval 3.6 to 4.7 nM). [Lys40(natIn-
DTPA)]exendin-3 and [Lys40(Ahx-DTPA-natIn)NH2]-exen-
din-4, previously tested on INS-1 cells, showed an IC50 of
62 nM (95% confidence interval 51 to 75 nM) and 89 nM
(95% confidence interval 66 to 120 nM) on the cell line
used in these experiments.
Internalisation assay
Figure 2B summarises the internalisation kinetics of 67Ga-
Ex4NOD40, 67Ga-Ex4NOD12 and 67Ga-Ex4NOD27 in
CHL-GLP-1R-positive cells over the course of 2 h. 67Ga-
Ex4NOD12 and 67Ga-Ex4NOD40 show a similar internal-
isation of 32.7% ± 4.1% and 35.0% ± 2.9%, respectively after
120 min. Ex4NOD27 shows both a slower and significantly
lower (p < 0.02) internalisation of 20.0% ± 3.9% after
120 min.
Plasma stability
Figure 3 illustrates the plasma stability in fresh human
blood plasma. Seventy-eight percent of 67Ga-Ex4NOD40,
94% of 67Ga-Ex4NOD12 and 90% of 67Ga-Ex4NOD27 were
intact after 48 h. The half-lives were 128, 560 and 360 h,
respectively.
Biodistribution
Figure 4 and Table 1 show the biodistribution of 68Ga-
Ex4NOD40, 68Ga-Ex4NOD12 and 68Ga-Ex4NOD27
after 2 h as well as the blocking experiment with add-
itionally pre-injected excess peptide. All compounds
showed a high specific tumour uptake as well as specific
uptake in the pancreas and lung. Generally, 68Ga-la-
belled Ex4NOD12 and Ex4NOD40 demonstrated very
similar uptake; 68Ga-Ex4NOD27, however, displayed a
significantly lower accumulation in the lung (p < 0.05)
and, at some time points, in the tumour (p < 0.05). The
renal uptake of all the 68Ga-labelled probes was high and
excess unlabelled peptide did not block the kidney up-
take indicating that it is not GLP-1 receptor mediated
which is in line with earlier observations [22].
Figure 2 Competition binding assay (A) and internalisation kinetics (B). (A) IC 50 values of natGa-Ex4NOD12, natGa-Ex4NOD27, natGa-Ex4NOD40,
exendin-4, [Lys40(natIn-DTPA)]exendin-3 and [Lys40(Ahx-DTPA-natIn)NH2]-exendin-4 in CHL-GLP-1R positive cells. A 120-fmol
67Ga-Ex4NOD40 with a specific
activity of 8.9 MBq/nmol was used as tracer. (B) Internalisation of 67Ga-Ex4NOD12, 67Ga-Ex4NOD27 and 67Ga-Ex4NOD40 in CHL-GLP-1R positive cells.
A 120-fmol 67Ga-labelled peptide was used as tracer. The values are corrected for non-specific binding determined by co-incubation with 1 μM
natGa-labelled peptide.
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The position of the chelator appears to affect the
in vivo kinetics of the peptide. Both 68Ga-Ex4NOD12
and 68Ga-Ex4NOD40 show a high uptake in the lung
that is increasing over the course of 2 h. 68Ga-
Ex4NOD27 in contrast exhibits a lower uptake which
in addition decreases with time. Kidney uptake seems
to be affected as well, as 68Ga-Ex4NOD12 shows a re-
duction of activity over time while the other two radi-
olabelled peptides seem to accumulate. Additionally,
68Ga-Ex4NOD12 shows the lowest non-specific uptake
tissue not expressing GLP-1R as well as in the blocking
experiments (tumour p < 0.04, lung p < 0.003). For the
pancreas, however, the uptake peaks at 1 h, while the
other two probes show an increasing uptake for the
time of the experiment.
Discussion
The GLP-1 receptor is specifically expressed on β-cells
and is a promising target for β-cell imaging. Radiolabelled
derivatives of exendin-4, a ligand for GLP-1R, have been
successfully used to image insulinoma in patients [10].
There are conflicting reports as to whether the conjuga-
tion site of the chelator affects the properties of the
peptides. Kirkpatrick et al. showed that both lysine resi-
dues at positions 12 and 27 are important for the affin-
ity to the GLP-1 receptor as they form salt bridges that
stabilise the binding [15]. However, experiments by Son
et al. revealed that conjugation of bile acid derivatives
to either K12 or K27 still result in a sub-nanomolar af-
finity of the peptide. In contrast, the conjugation at both
positions leads to a loss of affinity of a factor of at least
30, depending on the substrate [23]. Jin et al. were also
able to show that biotinylated exendin-4 derivatives
showed no significantly lower affinities compared to
unmodified exendin-4 when conjugated at the same
positions [17]. In contrast, the investigations of Kim
et al. on PEGylated exendin-4 derivatives led to the
conclusion that conjugations at both K27 and a C-
terminally added cysteine had similar affinities as exendin-
4, while the K12 derivative showed reduced binding to
the receptor [16].
In order to elucidate the effects of modifications on our
construct, we compared three 67/68Ga-labelled peptides
Ex4NOD12, Ex4NOD27 and Ex4NOD40 with different
conjugation positions of the chelator NODAGA, which al-
lows the incorporation of a variety of radio metals. CD
measurement shows the formation of an α-helix for all
three peptides similar to the unmodified exendin-4. In
addition, all peptides exhibit complete refolding to its ori-
ginal α-helical structure after denaturation at 94°C, the
temperature used for labelling. IC50-binding studies on
transfected CHL cells stably expressing the GLP-1 receptor
revealed that all modified peptides showed a 7- to 13-fold
lower binding compared to the unmodified exendin-4. Ga-
Ex4NOD12 showed the highest affinity to the receptor
whereas both Ga-Ex4NOD40 and Ga-Ex4NOD27 showed
to be similar, albeit lower binding affinities. This is in con-
trast to reports in which C-terminally modified exendin-4
derivatives show similar binding as the unmodified peptide
[11,16,24]. The differences to literature values can be attrib-
uted to the fact that different cell lines were used. The re-
sults show a 5- and 42-fold lower binding affinity compared
to the published data obtained on INS-1 cells, which indi-
cates an overall lower affinity of modified exendin deriva-
tives to the GLP-1 receptor in this cell line [24,25].
All peptides show a high metabolic stability in fresh
human blood plasma for up to 3 h. As imaging with
68Ga is usually performed within 1 to 2 h after injection,
the stability of the peptides is sufficient. Ga-Ex4NOD12
and Ga-Ex4NOD27 even show an improved stability
Figure 3 Plasma stability of 67Ga-Ex4NOD12, 67Ga-Ex4NOD27
and 67Ga-Ex4NOD40 in fresh human blood plasma. The
experiment was performed over the course of 48 h.
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over Ga-Ex4NOD40 for more than 48 h. The bulky che-
lator might influence the accessibility of intramolecular
cleavage sites of enzymes leading to a lowered metabolism.
Biodistribution in CD1 nu/nu mice with a subcutane-
ous CHL-GLP-1-receptor-positive tumour showed spe-
cific uptake in tumour and GLP-1-receptor-positive
tissue as well as high non-GLP-1R-mediated kidney ab-
sorption for all three peptides. However, both the
amount and kinetics of the accumulated activity differ.
Retained activity in GLP-1R-positive tissue in 68Ga-
Ex4NOD12- and 68Ga-Ex4NOD40-injected mice are
similar, while that in 68Ga-Ex4NOD27-injected mice
Figure 4 Biodistribution of 68Ga-Ex4NOD12, 68Ga-Ex4NOD27 and 68Ga-Ex4NOD40 in CD1 nu/nu mice with subcutaneous CHL-GLP-1R-
positive tumours. Values are mean percentages injected dose per gram tissue (n = 4. Error bars SD). Blocking was performed by pre-injection of
100 μg excess of the corresponding unlabelled compound. Mice were sacrificed 0.5, 1 and 2 h after injection. The significance between the 2 h
unblocked and blocked was tested by Student's unpaired t test (*p < 0.05; **p < 0.01).
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Table 1 Biodistribution of the 68Ga-labelled peptides in CD1 nu/nu mice
Biodistribution (%iA/g)
0.5 h 1 h 2 h 2 h blocked
Ex4NOD12
Blood 0.84 ± 0.11 0.32 ± 0.16 0.18 ± 0.01 0.19 ± 0.04
Heart 0.78 ± 0.13 0.44 ± 0.07 0.51 ± 0.35 0.26 ± 0.06
Lung 18.59 ± 2.62 22.67 ± 5.36 25.47 ± 2.02 0.37 ± 0.08
Spleen 1.06 ± 0.11 1.06 ± 0.56 0.44 ± 0.05 0.75 ± 0.31
Kidneys 142.52 ± 24.51 133.35 ± 22.18 104.20 ± 12.02 136.72 ± 9.41
Pancreas 5.57 ± 0.53 6.93 ± 2.64 4.52 ± 0.96 1.23 ± 0.91
Stomach 1.59 ± 0.78 0.77 ± 0.24 0.75 ± 0.49 0.20 ± 0.07
Intestines 0.83 ± 0.23 0.52 ± 0.05 0.74 ± 0.10 0.13 ± 0.02
Liver 1.09 ± 0.19 0.91 ± 0.19 0.31 ± 0.05 1.88 ± 0.23
Muscle 0.43 ± 0.11 0.21 ± 0.03 0.19 ± 0.07 0.26 ± 0.16
Bone 0.98 ± 0.90 0.42 ± 0.16 0.23 ± 0.02 0.36 ± 0.10
Tumour 9.44 ± 3.94 8.92 ± 1.08 8.29 ± 1.50 0.83 ± 0.17
Ex4NOD27
Blood 0.88 ± 0.09 0.36 ± 0.09 0.24 ± 0.04 0.23 ± 0.05
Heart 0.62 ± 0.05 0.44 ± 0.02 0.41 ± 0.04 0.27 ± 0.02
Lung 16.56 ± 2.74 13.79 ± 2.04 11.63 ± 4.51 0.43 ± 0.18
Spleen 0.81 ± 0.08 2.72 ± 0.55 0.89 ± 0.40 0.58 ± 0.30
Kidneys 117.21 ± 5.47 124.50 ± 12.13 143.00 ± 34.71 122.30 ± 35.13
Pancreas 4.10 ± 0.54 4.91 ± 1.61 6.89 ± 1.81 0.87 ± 0.10
Stomach 0.93 ± 0.16 0.92 ± 0.27 0.79 ± 0.39 0.19 ± 0.13
Intestines 0.40 ± 0.07 0.66 ± 0.19 0.71 ± 0.40 0.24 ± 0.11
Liver 1.36 ± 0.10 6.31 ± 0.27 1.04 ± 0.17 0.65 ± 0.22
Muscle 0.33 ± 0.04 0.38 ± 0.09 0.29 ± 0.05 0.18 ± 0.10
Bone 0.56 ± 0.16 0.89 ± 0.22 0.47 ± 0.08 0.29 ± 0.11
Tumour 7.26 ± 2.32 5.18 ± 0.98 4.69 ± 0.98 0.97 ± 0.07
Ex4NOD40
Blood 1.15 ± 0.37 0.72 ± 0.33 0.66 ± 0.17 0.48 ± 0.10
Heart 0.94 ± 0.34 0.56 ± 0.24 0.57 ± 0.08 0.41 ± 0.12
Lung 22.83 ± 8.04 26.28 ± 6.46 25.67 ± 7.94 0.77 ± 0.12
Spleen 1.73 ± 0.51 1.23 ± 0.37 1.60 ± 0.43 1.50 ± 0.38
Kidneys 101.14 ± 22.60 110.35 ± 24.27 127.51 ± 11.58 168.66 ± 48.22
Pancreas 5.05 ± 1.02 6.73 ± 1.65 6.80 ± 1.80 2.63 ± 1.34
Stomach 1.80 ± 0.48 0.82 ± 0.28 1.78 ± 0.67 0.34 ± 0.12
Intestines 1.01 ± 0.34 0.72 ± 0.17 1.19 ± 0.37 0.31 ± 0.03
Liver 2.71 ± 0.71 2.28 ± 0.44 2.47 ± 0.77 2.75 ± 1.13
Muscle 0.46 ± 0.20 0.34 ± 0.16 0.44 ± 0.17 0.33 ± 0.14
Bone 0.66 ± 0.16 0.58 ± 0.22 1.24 ± 0.67 0.75 ± 0.35
Tumour 7.30 ± 0.94 6.60 ± 0.35 9.04 ± 1.97 2.39 ± 0.87
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shows lower accumulation in some time points in the
tumour and the lung. As Ga-Ex4NOD40 and Ga-
Ex4NOD27 have similar IC50 values, comparable uptake
would be expected. Subsequent internalisation experiments,
however, revealed that internalisation of Ga-Ex4NOD27 is
significantly lower than the other two peptides.
One additional challenge when imaging β-cells is the lim-
ited amount of overall GLP-1 receptors available which re-
quires the administration of low amounts of peptide with a
high specific activity in order to avoid receptor blocking
[13]. One potential way to further increase the specific ac-
tivity and therefore reduce the amount of tracer necessary
to obtain a clear image is to attach several chelators to the
peptide allowing more radioactivity per molecule. Another
potential advantage of two conjugation sites might be the
attachment of multiple moieties to exendin-4, for example
a fluorescent dye and a chelator, which could be used as a
probe for dual imaging. These experiments show that con-
jugating NODAGA to either the lysines in position 12 or
40 and to a lesser extent in position 27, does not greatly in-
fluence the properties of the peptide and could be used as
potential attachment sites for various moieties. Brom et al.
have shown comparable results using the 68Ga-labelled
exendin derivative [Lys40(68Ga-DOTA)]exendin-3. Biodistri-
bution in Balb/c nude mice showed similar uptake in the
pancreas (6.7 ± 1.8%iA/g), INS-1 tumour (8.9 ± 3.1%iA/g)
and kidneys 1 h after injection [12]. 68Ga-Ex4NOD40
showed a slightly higher pancreas uptake, whereas the kid-
ney and tumour uptake were lower compared to [Lys40
(68Ga-DOTA)]exendin-3. For Ex4NOD12, the overall up-
take in the pancreas, tumour and kidney was higher, and for
Ex4NOD27, the pancreas and tumour uptake were lower,
while the kidney uptake was the same. Wild et al. performed
experiments with [Lys40 (Ahx-DOTA-68Ga)NH2]-exendin-4
in Rip1Tag2 mice with spontaneously occurring insulinoma
tumours [26]. As spontaneous and subcutaneous tumours
are inherently different, a direct comparison of tumour-to-
normal organ ratios between Wild's and our work is
difficult. Therefore, we compared uptake of our tracer in
GLP-1R-positive (pancreas) and GLP-1R-negative tissue
(muscle and kidneys) with data from Wild et al. The
pancreas-to-muscle ratio after of [Lys40 (Ahx-DOTA-68Ga)
NH2]-exendin-4 is lower compared to the peptides investi-
gated in this paper, while the pancreas-to-kidney ratios are
comparable or slightly higher, indicating a good target to
background contrast for the three tested peptides.
Conclusions
In conclusion, 68Ga-Ex4NOD12, 68Ga-Ex4NOD40 and, to
a lesser extent, 68Ga-Ex4NOD27 show comparable results
and demonstrate good properties for pancreatic β-cell im-
aging, as they show high uptake and retention in GLP-1R-
positive tumour and tissue. 68Ga as a radionuclide allows
fast and high specific labelling, with a half-life matching
the biological half-life of the peptide [27]. Our results
show that the lysines at positions 12 and 40 could be pref-
erentially used to modify exendin-4.
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